GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Return-on-Tangible-Equity

BioDelivery Sciences International (FRA:BD5) Return-on-Tangible-Equity : 287.45% (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioDelivery Sciences International's annualized net income for the quarter that ended in Dec. 2021 was €226.2 Mil. BioDelivery Sciences International's average shareholder tangible equity for the quarter that ended in Dec. 2021 was €78.7 Mil. Therefore, BioDelivery Sciences International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 was 287.45%.

The historical rank and industry rank for BioDelivery Sciences International's Return-on-Tangible-Equity or its related term are showing as below:

FRA:BD5' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4388.1   Med: -102.96   Max: 121.93
Current: 121.93

During the past 13 years, BioDelivery Sciences International's highest Return-on-Tangible-Equity was 121.93%. The lowest was -4,388.10%. And the median was -102.96%.

FRA:BD5's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.345 vs FRA:BD5: 121.93

BioDelivery Sciences International Return-on-Tangible-Equity Historical Data

The historical data trend for BioDelivery Sciences International's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Return-on-Tangible-Equity Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity - - 86.46 98.68

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.19 39.70 62.27 45.86 287.45

Competitive Comparison of BioDelivery Sciences International's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Return-on-Tangible-Equity falls into.



BioDelivery Sciences International Return-on-Tangible-Equity Calculation

BioDelivery Sciences International's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=75.101/( (42.861+109.349 )/ 2 )
=75.101/76.105
=98.68 %

BioDelivery Sciences International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=226.172/( (48.018+109.349)/ 2 )
=226.172/78.6835
=287.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2021) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


BioDelivery Sciences International  (FRA:BD5) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


BioDelivery Sciences International Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines